A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: Analysis from the EVEREST trial

Mihai Gheorghiade, Peter S. Pang, Andrew P. Ambrosy, Gloria Lan, Philip Schmidt, Gerasimos Filippatos, Marvin Konstam, Karl Swedberg, Thomas Cook, Brian Traver, Aldo Maggioni, John C Jr. Burnett, Liliana Grinfeld, James Udelson, Faiez Zannad

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Hospitalization for worsening chronic heart failure results in high post-discharge mortality, morbidity, and cost. However, thorough characterization, soon after discharge of patients with early post-discharge events has not been previously performed. The objectives of this study were to describe the baseline, in-hospital, and post-discharge clinical, laboratory, and neurohormonal profiles of patients hospitalized for worsening heart failure with reduced ejection fraction (EF) who die or are re-admitted for cardiovascular (CV) causes within 90 days of initial hospitalization. Retrospective analysis of 4,133 patients hospitalized for worsening heart failure with EF B40% in the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial, which randomized patients to tolvaptan or placebo, both in addition to standard therapy. Clinical and laboratory parameters were obtained within 48 h of admission, during hospitalization, and post-discharge weeks 1, 4, 8, and every 8 weeks thereafter for a median of 9.9 months. Patients with events within 90 days were compared with those with later/no events. All-cause mortality (ACM) and CV re-hospitalization were independently adjudicated. Within 90 days of admission, 395 patients (9.6%) died and 801 patients (19.4%) were re-hospitalized for CV causes. Significant baseline and longitudinal differences were seen between groups with early versus later ([90 days) or no events at 12 months post-randomization. Post-discharge outcomes were similar in the tolvaptan and placebo groups. Patients with early post-discharge events experienced clinically significant worsening in signs and symptoms, laboratory values, and neurohormonal parameters soon after discharge. Identifying these abnormalities may facilitate efforts to reduce post-discharge mortality and re-hospitalization.

Original languageEnglish (US)
Pages (from-to)485-509
Number of pages25
JournalHeart Failure Reviews
Volume17
Issue number3
DOIs
StatePublished - May 2012

Fingerprint

Heart Failure
Hospitalization
Mortality
Placebos
Patient Discharge
Patient Admission
Random Allocation
Vasopressins
Signs and Symptoms
Outcome Assessment (Health Care)
Morbidity
Costs and Cost Analysis
tolvaptan
Therapeutics

Keywords

  • Acute heart failure
  • Characterization
  • Mortality
  • Patient profiles
  • Re-hospitalization

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days : Analysis from the EVEREST trial. / Gheorghiade, Mihai; Pang, Peter S.; Ambrosy, Andrew P.; Lan, Gloria; Schmidt, Philip; Filippatos, Gerasimos; Konstam, Marvin; Swedberg, Karl; Cook, Thomas; Traver, Brian; Maggioni, Aldo; Burnett, John C Jr.; Grinfeld, Liliana; Udelson, James; Zannad, Faiez.

In: Heart Failure Reviews, Vol. 17, No. 3, 05.2012, p. 485-509.

Research output: Contribution to journalArticle

Gheorghiade, M, Pang, PS, Ambrosy, AP, Lan, G, Schmidt, P, Filippatos, G, Konstam, M, Swedberg, K, Cook, T, Traver, B, Maggioni, A, Burnett, JCJ, Grinfeld, L, Udelson, J & Zannad, F 2012, 'A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: Analysis from the EVEREST trial', Heart Failure Reviews, vol. 17, no. 3, pp. 485-509. https://doi.org/10.1007/s10741-011-9280-0
Gheorghiade, Mihai ; Pang, Peter S. ; Ambrosy, Andrew P. ; Lan, Gloria ; Schmidt, Philip ; Filippatos, Gerasimos ; Konstam, Marvin ; Swedberg, Karl ; Cook, Thomas ; Traver, Brian ; Maggioni, Aldo ; Burnett, John C Jr. ; Grinfeld, Liliana ; Udelson, James ; Zannad, Faiez. / A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days : Analysis from the EVEREST trial. In: Heart Failure Reviews. 2012 ; Vol. 17, No. 3. pp. 485-509.
@article{d2eb1e2c594c465d9473f8dbd98441b8,
title = "A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: Analysis from the EVEREST trial",
abstract = "Hospitalization for worsening chronic heart failure results in high post-discharge mortality, morbidity, and cost. However, thorough characterization, soon after discharge of patients with early post-discharge events has not been previously performed. The objectives of this study were to describe the baseline, in-hospital, and post-discharge clinical, laboratory, and neurohormonal profiles of patients hospitalized for worsening heart failure with reduced ejection fraction (EF) who die or are re-admitted for cardiovascular (CV) causes within 90 days of initial hospitalization. Retrospective analysis of 4,133 patients hospitalized for worsening heart failure with EF B40{\%} in the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial, which randomized patients to tolvaptan or placebo, both in addition to standard therapy. Clinical and laboratory parameters were obtained within 48 h of admission, during hospitalization, and post-discharge weeks 1, 4, 8, and every 8 weeks thereafter for a median of 9.9 months. Patients with events within 90 days were compared with those with later/no events. All-cause mortality (ACM) and CV re-hospitalization were independently adjudicated. Within 90 days of admission, 395 patients (9.6{\%}) died and 801 patients (19.4{\%}) were re-hospitalized for CV causes. Significant baseline and longitudinal differences were seen between groups with early versus later ([90 days) or no events at 12 months post-randomization. Post-discharge outcomes were similar in the tolvaptan and placebo groups. Patients with early post-discharge events experienced clinically significant worsening in signs and symptoms, laboratory values, and neurohormonal parameters soon after discharge. Identifying these abnormalities may facilitate efforts to reduce post-discharge mortality and re-hospitalization.",
keywords = "Acute heart failure, Characterization, Mortality, Patient profiles, Re-hospitalization",
author = "Mihai Gheorghiade and Pang, {Peter S.} and Ambrosy, {Andrew P.} and Gloria Lan and Philip Schmidt and Gerasimos Filippatos and Marvin Konstam and Karl Swedberg and Thomas Cook and Brian Traver and Aldo Maggioni and Burnett, {John C Jr.} and Liliana Grinfeld and James Udelson and Faiez Zannad",
year = "2012",
month = "5",
doi = "10.1007/s10741-011-9280-0",
language = "English (US)",
volume = "17",
pages = "485--509",
journal = "Heart Failure Reviews",
issn = "1382-4147",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days

T2 - Analysis from the EVEREST trial

AU - Gheorghiade, Mihai

AU - Pang, Peter S.

AU - Ambrosy, Andrew P.

AU - Lan, Gloria

AU - Schmidt, Philip

AU - Filippatos, Gerasimos

AU - Konstam, Marvin

AU - Swedberg, Karl

AU - Cook, Thomas

AU - Traver, Brian

AU - Maggioni, Aldo

AU - Burnett, John C Jr.

AU - Grinfeld, Liliana

AU - Udelson, James

AU - Zannad, Faiez

PY - 2012/5

Y1 - 2012/5

N2 - Hospitalization for worsening chronic heart failure results in high post-discharge mortality, morbidity, and cost. However, thorough characterization, soon after discharge of patients with early post-discharge events has not been previously performed. The objectives of this study were to describe the baseline, in-hospital, and post-discharge clinical, laboratory, and neurohormonal profiles of patients hospitalized for worsening heart failure with reduced ejection fraction (EF) who die or are re-admitted for cardiovascular (CV) causes within 90 days of initial hospitalization. Retrospective analysis of 4,133 patients hospitalized for worsening heart failure with EF B40% in the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial, which randomized patients to tolvaptan or placebo, both in addition to standard therapy. Clinical and laboratory parameters were obtained within 48 h of admission, during hospitalization, and post-discharge weeks 1, 4, 8, and every 8 weeks thereafter for a median of 9.9 months. Patients with events within 90 days were compared with those with later/no events. All-cause mortality (ACM) and CV re-hospitalization were independently adjudicated. Within 90 days of admission, 395 patients (9.6%) died and 801 patients (19.4%) were re-hospitalized for CV causes. Significant baseline and longitudinal differences were seen between groups with early versus later ([90 days) or no events at 12 months post-randomization. Post-discharge outcomes were similar in the tolvaptan and placebo groups. Patients with early post-discharge events experienced clinically significant worsening in signs and symptoms, laboratory values, and neurohormonal parameters soon after discharge. Identifying these abnormalities may facilitate efforts to reduce post-discharge mortality and re-hospitalization.

AB - Hospitalization for worsening chronic heart failure results in high post-discharge mortality, morbidity, and cost. However, thorough characterization, soon after discharge of patients with early post-discharge events has not been previously performed. The objectives of this study were to describe the baseline, in-hospital, and post-discharge clinical, laboratory, and neurohormonal profiles of patients hospitalized for worsening heart failure with reduced ejection fraction (EF) who die or are re-admitted for cardiovascular (CV) causes within 90 days of initial hospitalization. Retrospective analysis of 4,133 patients hospitalized for worsening heart failure with EF B40% in the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial, which randomized patients to tolvaptan or placebo, both in addition to standard therapy. Clinical and laboratory parameters were obtained within 48 h of admission, during hospitalization, and post-discharge weeks 1, 4, 8, and every 8 weeks thereafter for a median of 9.9 months. Patients with events within 90 days were compared with those with later/no events. All-cause mortality (ACM) and CV re-hospitalization were independently adjudicated. Within 90 days of admission, 395 patients (9.6%) died and 801 patients (19.4%) were re-hospitalized for CV causes. Significant baseline and longitudinal differences were seen between groups with early versus later ([90 days) or no events at 12 months post-randomization. Post-discharge outcomes were similar in the tolvaptan and placebo groups. Patients with early post-discharge events experienced clinically significant worsening in signs and symptoms, laboratory values, and neurohormonal parameters soon after discharge. Identifying these abnormalities may facilitate efforts to reduce post-discharge mortality and re-hospitalization.

KW - Acute heart failure

KW - Characterization

KW - Mortality

KW - Patient profiles

KW - Re-hospitalization

UR - http://www.scopus.com/inward/record.url?scp=84861553275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861553275&partnerID=8YFLogxK

U2 - 10.1007/s10741-011-9280-0

DO - 10.1007/s10741-011-9280-0

M3 - Article

C2 - 21932146

AN - SCOPUS:84861553275

VL - 17

SP - 485

EP - 509

JO - Heart Failure Reviews

JF - Heart Failure Reviews

SN - 1382-4147

IS - 3

ER -